Merus to Participate in Upcoming Investor Conferences
Guggenheim Healthcare Talks/2022 Oncology Conference(fireside chat): Thursday, February 10at 10:30-10:55 a.m. ET
- Citi's 2022 Virtual Immuno-Oncology Summit (fireside chat including
Andrew Joe, M.D., Merus Chief Medical Officer): February 16at 1:30-2:30 p.m. ET
- 11th Annual
SVB Leerink Global Healthcare Conference(presentation): Thursday, February 17at 12:00-12:30 p.m. ET
The webcasts of the presentations will be contemporaneously available on the Investors page of the Company's website. Archived presentations will also be available there for a limited time after the event.
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.
Investor and Media Inquiries:
Kathleen FarrenMerus N.V. IR/Corp Comms 617-230-4165 firstname.lastname@example.org